January 30, 2017
Realm Therapeutics asks FDA’s approval for its first IND for atopic dermatitis treatment
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).